{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T19:50:10Z","timestamp":1787946610264,"version":"build-2784847793"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.intimp.2015.07.017","type":"journal-article","created":{"date-parts":[[2015,7,28]],"date-time":"2015-07-28T17:45:33Z","timestamp":1438105533000},"page":"596-603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Intravenous immunoglobulin replacement induces an in vivo reduction of inflammatory monocytes and retains the monocyte ability to respond to bacterial stimulation in patients with common variable immunodeficiencies"],"prefix":"10.1016","volume":"28","author":[{"given":"Filomena Monica","family":"Cavaliere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Prezzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Bilotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Pulvirenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8947-0097","authenticated-orcid":false,"given":"Metello","family":"Iacobini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3328-7584","authenticated-orcid":false,"given":"Isabella","family":"Quinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2015.07.017_bb0005","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","article-title":"Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology","volume":"117","author":"Orange","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2015.07.017_bb0010","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.clim.2009.10.003","article-title":"Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: a working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology","volume":"135","author":"Yong","year":"2010","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.intimp.2015.07.017_bb0015","doi-asserted-by":"crossref","first-page":"S182","DOI":"10.1016\/j.jaci.2009.07.053","article-title":"Primary immunodeficiencies","volume":"125","author":"Notarangelo","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2015.07.017_bb0020","doi-asserted-by":"crossref","first-page":"435","DOI":"10.7326\/0003-4819-101-4-435","article-title":"Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease","volume":"101","author":"Cunningham-Rundles","year":"1984","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.intimp.2015.07.017_bb0025","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clim.2010.06.012","article-title":"Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies","volume":"137","author":"Orange","year":"2010","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.intimp.2015.07.017_bb0030","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s10875-007-9075-1","article-title":"Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency","volume":"27","author":"Quinti","year":"2007","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.intimp.2015.07.017_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2014.00629","article-title":"Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in Europe","volume":"5","author":"Kerr","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2015.07.017_bb0040","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.autrev.2012.02.006","article-title":"Intravenous immunoglobulin: exploiting the potential of natural antibodies","volume":"11","author":"Kaveri","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2015.07.017_bb0045","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2249.2011.04387.x","article-title":"Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy","volume":"2","author":"Kaveri","year":"2011","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2015.07.017_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2014.00674","article-title":"Immunomodulation by IVIg and the role of Fc-gamma receptors: classic mechanisms of action after all?","volume":"5","author":"Nagelkerke","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2015.07.017_bb0055","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.clim.2011.01.002","article-title":"Preparations of intravenous immunoglobulins diminish the number and proinflammatory response of CD14+CD16++ monocytes in common variable immunodeficiency (CVID) patients","volume":"139","author":"Siedlar","year":"2011","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.intimp.2015.07.017_bb0060","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1749-6632.1997.tb46269.x","article-title":"Host tissue damage by phagocytes","volume":"832","author":"Ricevuti","year":"1997","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.intimp.2015.07.017_bb0065","doi-asserted-by":"crossref","first-page":"e57082","DOI":"10.1371\/journal.pone.0057082","article-title":"Phagocytosis is the main CR3-mediated function affected by the lupus-associated variant of CD11b in human myeloid cells","volume":"8","author":"Fossati-Jimack","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2015.07.017_bb0070","doi-asserted-by":"crossref","first-page":"22121","DOI":"10.1074\/jbc.M002788200","article-title":"Siglec-9, a novel sialic acid binding member of the immunoglobulin superfamily expressed broadly on human blood leukocytes","volume":"275","author":"Zhang","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2015.07.017_bb0075","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nri2056","article-title":"Siglecs and their roles in the immune system","volume":"7","author":"Crocker","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2015.07.017_bb0080","doi-asserted-by":"crossref","first-page":"6841","DOI":"10.4049\/jimmunol.173.11.6841","article-title":"The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells","volume":"173","author":"Avril","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2015.07.017_bb0085","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1182\/blood-2008-11-187302","article-title":"Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response","volume":"113","author":"Carlin","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2015.07.017_bb0090","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1182\/blood-2010-02-258558","article-title":"Nomenclature of monocytes and dendritic cells in blood","volume":"116","author":"Ziegler-Heitbrock","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2015.07.017_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2013.00023","article-title":"Toward a refined definition of monocyte subsets","volume":"4","author":"Ziegler-Heitbrock","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2015.07.017_bb0100","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1365-2249.2007.03326.x","article-title":"Increased CD11b expression on polymorphonuclear leucocytes and cytokine profiles in patients with Kawasaki disease","volume":"148","author":"Kobayashi","year":"2007","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2015.07.017_bb0105","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1182\/blood-2010-12-326355","article-title":"Gene expression profiling reveals the defining features of the classical, intermediate and nonclassical human monocyte subsets","volume":"118","author":"Wong","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2015.07.017_bb0110","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12026-012-8297-3","article-title":"The three human monocyte subsets: implications for health and disease","volume":"53","author":"Wong","year":"2012","journal-title":"Immunol. Res."},{"key":"10.1016\/j.intimp.2015.07.017_bb0115","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1182\/blood.V87.1.373.373","article-title":"Differential cytokine expression in human blood monocyte subpopulations: a polymerase chain reaction analysis","volume":"87","author":"Frankenberger","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2015.07.017_bb0120","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.4049\/jimmunol.168.7.3536","article-title":"The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF","volume":"168","author":"Belge","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2015.07.017_bb0125","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1365-2249.2012.04620.x","article-title":"Monocyte activation is a feature of common variable immunodeficiency irrespective of plasma lipopolysaccharide levels","volume":"169","author":"Barbosa","year":"2012","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2015.07.017_bb0130","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.jaci.2010.02.040","article-title":"Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22years","volume":"125","author":"Lucas","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2015.07.017_bb0135","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1182\/blood-2007-11-124545","article-title":"Common variable immunodeficiency disorders: division into distinct clinical phenotypes","volume":"112","author":"Chapel","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2015.07.017_bb0140","doi-asserted-by":"crossref","first-page":"5625","DOI":"10.4049\/jimmunol.1301260","article-title":"Intravenous immunoglobulin treatment in humans suppresses dendritic cell function via stimulation of IL-4 and IL-13 production","volume":"192","author":"Tjon","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2015.07.017_bb0145","doi-asserted-by":"crossref","first-page":"637","DOI":"10.3389\/fimmu.2014.00637","article-title":"Persistent immune activation in CVID and the role of IVIg in its suppression","volume":"5","author":"Paquin-Proulx","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2015.07.017_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0075199","article-title":"IVIg immune reconstitution treatment alleviates the state of persistent immune activation and suppressed CD4 T cell counts in CVID","volume":"8","author":"Paquin-Proulx","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2015.07.017_bb0155","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1046\/j.1365-2249.1998.00697.x","article-title":"Human intravenous immunoglobulin (IVIG) preparations degranulate human neutrophils in vitro","volume":"114","author":"Teeling","year":"1998","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2015.07.017_bb0160","doi-asserted-by":"crossref","first-page":"332","DOI":"10.4049\/jimmunol.173.1.332","article-title":"Monomeric IgG in intravenous Ig preparations is a functional antagonist of FcgammaRII and FcgammaRIIIb","volume":"173","author":"van Mirre","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2015.07.017_bb0165","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1600-0463.2005.apm_05.x","article-title":"Intravenous immunoglobulin preparations promote apoptosis in lipopolysaccharide-stimulated neutrophils via an oxygen-dependent pathway in vitro","volume":"113","author":"Takeshita","year":"2005","journal-title":"APMIS"},{"key":"10.1016\/j.intimp.2015.07.017_bb0170","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.clim.2011.02.002","article-title":"Another new mechanism of action of IGIV","volume":"139","author":"Berger","year":"2011","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.intimp.2015.07.017_bb0175","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clim.2012.07.008","article-title":"High-dose intravenous immunoglobulin does not reduce the numbers of circulating CD14(+)CD16(++) monocytes in patients with inflammatory disorders","volume":"145","author":"Tjon","year":"2012","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.intimp.2015.07.017_bb0180","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/boc.201200013","article-title":"Signalling mechanism of the leukocyte integrin \u03b1M\u03b22: current and future perspectives","volume":"104","author":"Lim","year":"2012","journal-title":"Biol. Cell."},{"key":"10.1016\/j.intimp.2015.07.017_bb0185","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1182\/blood-2004-10-4112","article-title":"Siglec-9 transduces apoptotic and nonapoptotic death signals into neutrophils depending on the proinflammatory cytokine environment","volume":"106","author":"von Gunten","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2015.07.017_bb0190","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1007\/s10875-010-9411-8","article-title":"Cell death modulation by intravenous immunoglobulin","volume":"1","author":"von Gunten","year":"2010","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.intimp.2015.07.017_bb0195","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/cyto.1134","article-title":"Relationship between oxidative burst activity and CD11b expression in neutrophils and monocytes from healthy individuals: effects of race and gender","volume":"46","author":"Siddiqi","year":"2001","journal-title":"Cytometry"},{"key":"10.1016\/j.intimp.2015.07.017_bb0200","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1365-2249.1994.tb06073.x","article-title":"Enhanced generation of reactive oxygen species in monocytes from patients with common variable immunodeficiency","volume":"97","author":"Aukrust","year":"1994","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2015.07.017_bb0205","doi-asserted-by":"crossref","first-page":"417","DOI":"10.4049\/jimmunol.171.1.417","article-title":"Direct binding of Toll-like receptor 2 to zymosan, and zymosan-induced NF-kappa B activation and TNF-alpha secretion are down-regulated by lung collectin surfactant protein A","volume":"171","author":"Sato","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2015.07.017_bb0210","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/emboj\/18.5.1095","article-title":"Crystal structure of the soluble form of the human fcgamma-receptor IIb: a new member of the immunoglobulin superfamily at 1.7 A resolution","volume":"5","author":"Sondermann","year":"1999","journal-title":"EMBO J."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757691530031X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757691530031X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:41:29Z","timestamp":1755650489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757691530031X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S156757691530031X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2015.07.017","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous immunoglobulin replacement induces an in vivo reduction of inflammatory monocytes and retains the monocyte ability to respond to bacterial stimulation in patients with common variable immunodeficiencies","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2015.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}